6,014 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Kestra Investment Management LLC

Kestra Investment Management LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 6,014 shares of the biopharmaceutical company’s stock, valued at approximately $2,391,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $32,000. Aster Capital Management DIFC Ltd acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $297.45 on Tuesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market cap of $39.71 billion, a price-to-earnings ratio of 81.27 and a beta of 0.31. The stock has a 50 day simple moving average of $310.76 and a 200-day simple moving average of $358.07. Alnylam Pharmaceuticals, Inc. has a 1-year low of $284.19 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the company posted ($0.44) EPS. The business’s quarterly revenue was up 96.4% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Insider Activity

In related news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Pushkal Garg sold 1,775 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the sale, the executive vice president owned 23,406 shares of the company’s stock, valued at $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 21,255 shares of company stock valued at $6,930,337 in the last three months. Company insiders own 0.86% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Citigroup assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target for the company. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 4th. HC Wainwright reissued a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 5th. Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Morgan Stanley reduced their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $463.13.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.